Previous 10 | Next 10 |
home / stock / crtpf / crtpf news
Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease now being initiated at clinical centers in the United States Oakville, Ontario--(Newsfile Corp. - Dec...
The first pharmaceutically produced THC-free* extra-strength cannabidiol (CBD) Oakville, Ontario--(Newsfile Corp. - October 20, 2020) - Cardiol Therapeutics Inc. ( TSX: CRDL ) ( OTCQX: CRTPF ) (" Cardiol " or the " Company "), a clinical-stage biotechnology company focused on developi...
Redondo Beach, California--(Newsfile Corp. - September 30, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering a potentially major development in the quest to improve outc...
The FDA has signed off on a U.S. Phase 2/3 clinical trial evaluating Cardiol Therapeutics' (CRTPF) CardioRx, an extra-strength formulation of cannabidiol, in 422 hospitalized COVID-19 patients with prior histories of of risk factors cardiovascular disease ((CVD)).The study's objective i...
Trial will take place at major U.S. centers and examine the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease (CVD) Oakville, Ontario--(Newsfile Corp. - September 25, 2020) - Cardiol Th...
Redondo Beach, California--(Newsfile Corp. - September 16, 2020) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering Cardiol Therapeutics Inc .'s (TSX: CRDL) (OTCQX: CRTPF) in...
Oakville, Ontario--(Newsfile Corp. - September 15, 2020) - Cardiol Therapeutics Inc. ( TSX: CRDL ) ( OTCQX: CRTPF ) (" Cardiol " or the " Company "), a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular diseases, including heart failure ...
Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and ind...
Oakville, Ontario--(Newsfile Corp. - August 26, 2020) - Cardiol Therapeutics Inc. ( TSX: CRDL ) ( OTCQX: CRTPF ) (" Cardiol " or the " Company "), a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular diseases, including heart failure and...
August 6, 2020 FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – August 6, 2020 – In the last 18 years, viral disease epidemics have killed almost 600,000 people across the globe. Today’s pandemic is quickly adding...
News, Short Squeeze, Breakout and More Instantly...
Cardiol Therapeutics Company Name:
CRTPF Stock Symbol:
OTCMKTS Market:
Oakville, Ontario--(Newsfile Corp. - August 9, 2021) - Cardiol Therapeutics Inc. ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced to...
Oakville, Ontario--(Newsfile Corp. - July 7, 2021) - Cardiol Therapeutics Inc. ( TSX: CRDL ) ( OTCQX: CRTPF ) ( FSE: CT9 ) (" Cardiol " or the " Company "), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardio...
Oakville, Ontario--(Newsfile Corp. - June 30, 2021) - Cardiol Therapeutics Inc. ( TSX: CRDL ) ( OTCQX: CRTPF ) ( FSE: CT9 ) (" Cardiol " or the " Company "), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardi...